During the day, Scandion Oncology’s executive management will provide a corporate strategy update, a deep dive into the clinical strategy and the business opportunities to pursue our goal of becoming The Cancer Drug Resistance Company.
Specific details will be provided in August, but please save the date or register now at https://www.lyyti.fi/reg/Capital_Markets_Day_Scandion_Oncology_7500
The presentation will be held in English.
For further information regarding Scandion Oncology A/S, please contact:
Bo Rode Hansen, President & CEO
Phone: +45 3810 2017
The information was provided by the contact person above for publication on July 19, 2021.
About Scandion Oncology A/S
Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.
For more information, please visit www.scandiononcology.com and sign up for news releases.
For frequent updates, please also follow us on LinkedIn and Twitter.
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at firstname.lastname@example.org or +46 (0) 40 200 250.